

## Halofuginone Formulation

Version 5.1      Revision Date: 30.09.2023      SDS Number: 862857-00018      Date of last issue: 04.04.2023  
Date of first issue: 26.08.2016

---

### SECTION 1. IDENTIFICATION

Product name : Halofuginone Formulation

#### Manufacturer or supplier's details

Company : MSD

Address : Talcahuano 750, 6th floor, Ciudad Autonoma  
Buenos Aires, Argentina C1013AAP

Telephone : 908-740-4000

Emergency telephone : 1-908-423-6000

E-mail address : EHSDATASTEWARD@msd.com

#### Recommended use of the chemical and restrictions on use

Recommended use : Veterinary product

Restrictions on use : Not applicable

---

### SECTION 2. HAZARDS IDENTIFICATION

#### GHS Classification

Skin corrosion/irritation : Category 2

Serious eye damage/eye irritation : Category 2A

Short-term (acute) aquatic hazard : Category 3

Long-term (chronic) aquatic hazard : Category 3

#### GHS label elements

Hazard pictograms :



Signal Word : Warning

Hazard Statements : H315 Causes skin irritation.  
H319 Causes serious eye irritation.  
H412 Harmful to aquatic life with long lasting effects.

Precautionary Statements : **Prevention:**  
P264 Wash skin thoroughly after handling.

## Halofuginone Formulation

Version 5.1      Revision Date: 30.09.2023      SDS Number: 862857-00018      Date of last issue: 04.04.2023  
 Date of first issue: 26.08.2016

P273 Avoid release to the environment.  
 P280 Wear protective gloves/ eye protection/ face protection.

**Response:**

P302 + P352 IF ON SKIN: Wash with plenty of water.  
 P305 + P351 + P338 IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing.  
 P332 + P313 If skin irritation occurs: Get medical advice/ attention.  
 P337 + P313 If eye irritation persists: Get medical advice/ attention.  
 P362 + P364 Take off contaminated clothing and wash it before reuse.

**Disposal:**

P501 Dispose of contents/ container to an approved waste disposal plant.

**Other hazards which do not result in classification**

None known.

**SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS**

Substance / Mixture : Mixture

**Components**

Chemical name	CAS-No.	Concentration (% w/w)
Lactic acid	50-21-5	>= 1 -< 3
Halofuginone	82186-71-8	>= 0,025 -< 0,1

**SECTION 4. FIRST AID MEASURES**

General advice : In the case of accident or if you feel unwell, seek medical advice immediately.  
 When symptoms persist or in all cases of doubt seek medical advice.

If inhaled : If inhaled, remove to fresh air.  
 Get medical attention if symptoms occur.

In case of skin contact : In case of contact, immediately flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.  
 Get medical attention.  
 Wash clothing before reuse.  
 Thoroughly clean shoes before reuse.

In case of eye contact : In case of contact, immediately flush eyes with plenty of water for at least 15 minutes.  
 If easy to do, remove contact lens, if worn.  
 Get medical attention.

If swallowed : If swallowed, DO NOT induce vomiting.  
 Get medical attention if symptoms occur.  
 Rinse mouth thoroughly with water.

Most important symptoms : Causes skin irritation.

## Halofuginone Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
5.1	30.09.2023	862857-00018	Date of first issue: 26.08.2016

---

and effects, both acute and delayed  
 Causes serious eye irritation.

Protection of first-aiders : First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).

Notes to physician : Treat symptomatically and supportively.

---

### SECTION 5. FIRE-FIGHTING MEASURES

Suitable extinguishing media : Water spray  
 Alcohol-resistant foam  
 Carbon dioxide (CO<sub>2</sub>)  
 Dry chemical

Unsuitable extinguishing media : None known.

Specific hazards during fire fighting : Exposure to combustion products may be a hazard to health.

Hazardous combustion products : Carbon oxides

Specific extinguishing methods : Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.  
 Use water spray to cool unopened containers.  
 Remove undamaged containers from fire area if it is safe to do so.  
 Evacuate area.

Special protective equipment for fire-fighters : In the event of fire, wear self-contained breathing apparatus.  
 Use personal protective equipment.

---

### SECTION 6. ACCIDENTAL RELEASE MEASURES

Personal precautions, protective equipment and emergency procedures : Use personal protective equipment.  
 Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).

Environmental precautions : Avoid release to the environment.  
 Prevent further leakage or spillage if safe to do so.  
 Prevent spreading over a wide area (e.g., by containment or oil barriers).  
 Retain and dispose of contaminated wash water.  
 Local authorities should be advised if significant spillages cannot be contained.

Methods and materials for containment and cleaning up : Soak up with inert absorbent material.  
 For large spills, provide diking or other appropriate containment to keep material from spreading. If diked material can be pumped, store recovered material in appropriate container.  
 Clean up remaining materials from spill with suitable absorbent.  
 Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable.  
 Sections 13 and 15 of this SDS provide information regarding

## Halofuginone Formulation

Version 5.1      Revision Date: 30.09.2023      SDS Number: 862857-00018      Date of last issue: 04.04.2023  
 Date of first issue: 26.08.2016

certain local or national requirements.

## SECTION 7. HANDLING AND STORAGE

- Technical measures : See Engineering measures under EXPOSURE CONTROLS/PERSONAL PROTECTION section.
- Local/Total ventilation : Use only with adequate ventilation.
- Advice on safe handling : Do not get on skin or clothing.  
 Avoid inhalation of vapor or mist.  
 Do not swallow.  
 Do not get in eyes.  
 Wash skin thoroughly after handling.  
 Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment  
 Take care to prevent spills, waste and minimize release to the environment.
- Conditions for safe storage : Keep in properly labeled containers.  
 Store in accordance with the particular national regulations.
- Materials to avoid : Do not store with the following product types:  
 Strong oxidizing agents  
 Gases

## SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

## Ingredients with workplace control parameters

Components	CAS-No.	Value type (Form of exposure)	Control parameters / Permissible concentration	Basis
Halofuginone	82186-71-8	TWA	5 µg/m <sup>3</sup> (OEB 4)	Internal
Further information: DSEN, Skin				
		Wipe limit	50 µg/100 cm <sup>2</sup>	Internal

- Engineering measures** : All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.  
 Essentially no open handling permitted.  
 Use closed processing systems or containment technologies.  
 If handled in a laboratory, use a properly designed biosafety cabinet, fume hood, or other containment device if the potential exists for aerosolization. If this potential does not exist, handle over lined trays or benchtops.

**Personal protective equipment**

- Respiratory protection : If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.
- Filter type : Organic vapor Type
- Hand protection
- Material : Chemical-resistant gloves

## Halofuginone Formulation

Version 5.1      Revision Date: 30.09.2023      SDS Number: 862857-00018      Date of last issue: 04.04.2023  
Date of first issue: 26.08.2016

---

Remarks	:	Consider double gloving.
Eye protection	:	Wear safety glasses with side shields or goggles. If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles. Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.
Skin and body protection	:	Work uniform or laboratory coat. Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable suits) to avoid exposed skin surfaces. Use appropriate degowning techniques to remove potentially contaminated clothing.
Hygiene measures	:	If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash contaminated clothing before re-use. The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.

---

### SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES

Appearance	:	liquid
Color	:	yellow
Odor	:	odorless
Odor Threshold	:	No data available
pH	:	2,1 - 3
Melting point/freezing point	:	No data available
Initial boiling point and boiling range	:	No data available
Flash point	:	No data available
Evaporation rate	:	No data available
Flammability (solid, gas)	:	Not applicable
Flammability (liquids)	:	No data available
Upper explosion limit / Upper flammability limit	:	No data available
Lower explosion limit / Lower flammability limit	:	No data available

## Halofuginone Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
5.1	30.09.2023	862857-00018	Date of first issue: 26.08.2016

---

Vapor pressure	:	No data available
Relative vapor density	:	No data available
Density	:	No data available
Solubility(ies)		
Water solubility	:	No data available
Partition coefficient: n-octanol/water	:	No data available
Autoignition temperature	:	No data available
Decomposition temperature	:	No data available
Viscosity		
Viscosity, kinematic	:	No data available
Explosive properties	:	Not explosive
Oxidizing properties	:	The substance or mixture is not classified as oxidizing.
Molecular weight	:	No data available
Particle size	:	No data available

---

**SECTION 10. STABILITY AND REACTIVITY**

Reactivity	:	Not classified as a reactivity hazard.
Chemical stability	:	Stable under normal conditions.
Possibility of hazardous reactions	:	Can react with strong oxidizing agents.
Conditions to avoid	:	None known.
Incompatible materials	:	Oxidizing agents
Hazardous decomposition products	:	No hazardous decomposition products are known.

---

**SECTION 11. TOXICOLOGICAL INFORMATION**

Information on likely routes of exposure	:	Inhalation Skin contact Ingestion Eye contact
--	---	--

**Acute toxicity**

Not classified based on available information.

**Product:**

Acute oral toxicity	:	Acute toxicity estimate: > 5.000 mg/kg Method: Calculation method
Acute inhalation toxicity	:	Acute toxicity estimate: > 10 mg/l Exposure time: 4 h

## Halofuginone Formulation

Version 5.1      Revision Date: 30.09.2023      SDS Number: 862857-00018      Date of last issue: 04.04.2023  
Date of first issue: 26.08.2016

---

Test atmosphere: dust/mist  
Method: Calculation method

### Components:

#### **Lactic acid:**

- Acute oral toxicity : LD50 (Rat): > 2.000 mg/kg  
Remarks: Based on data from similar materials
- Acute inhalation toxicity : LC50 (Rat): > 5 mg/l  
Exposure time: 4 h  
Test atmosphere: dust/mist  
Method: OECD Test Guideline 403  
Assessment: Corrosive to the respiratory tract.  
Remarks: Based on data from similar materials
- Acute dermal toxicity : LD50 (Rabbit): > 2.000 mg/kg  
Assessment: The substance or mixture has no acute dermal toxicity  
Remarks: Based on data from similar materials

#### **Halofuginone:**

- Acute oral toxicity : LD50 (Rat): 30 mg/kg  
LD50 (Mouse): 5 mg/kg
- Acute inhalation toxicity : LC50 (Rat): 0,053 mg/l  
Test atmosphere: dust/mist
- Acute dermal toxicity : LD50 (Rabbit): 16 mg/kg

#### **Skin corrosion/irritation**

Causes skin irritation.

### Components:

#### **Lactic acid:**

- Species : Rabbit  
Method : OECD Test Guideline 404  
Result : Corrosive after 1 to 4 hours of exposure  
Remarks : Based on data from similar materials

#### **Halofuginone:**

- Species : Rabbit  
Result : Skin irritation

#### **Serious eye damage/eye irritation**

Causes serious eye irritation.

## Halofuginone Formulation

Version 5.1      Revision Date: 30.09.2023      SDS Number: 862857-00018      Date of last issue: 04.04.2023  
Date of first issue: 26.08.2016

---

### Components:

#### **Lactic acid:**

Species : Chicken eye  
Remarks : Based on data from similar materials  
  
Result : Irreversible effects on the eye

#### **Halofuginone:**

Result : Severe irritation

### **Respiratory or skin sensitization**

#### **Skin sensitization**

Not classified based on available information.

#### **Respiratory sensitization**

Not classified based on available information.

### Components:

#### **Lactic acid:**

Test Type : Buehler Test  
Routes of exposure : Skin contact  
Species : Guinea pig  
Result : negative  
Remarks : Based on data from similar materials

#### **Halofuginone:**

Routes of exposure : Dermal  
Species : Guinea pig  
Result : Sensitizer

### **Germ cell mutagenicity**

Not classified based on available information.

### Components:

#### **Lactic acid:**

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)  
Method: OECD Test Guideline 471  
Result: negative  
Remarks: Based on data from similar materials

Test Type: In vitro mammalian cell gene mutation test  
Method: OECD Test Guideline 476  
Result: negative  
Remarks: Based on data from similar materials

Test Type: Chromosome aberration test in vitro  
Method: OECD Test Guideline 473  
Result: negative  
Remarks: Based on data from similar materials



## Halofuginone Formulation

Version 5.1      Revision Date: 30.09.2023      SDS Number: 862857-00018      Date of last issue: 04.04.2023  
Date of first issue: 26.08.2016

---

### Halofuginone:

Genotoxicity in vitro : Test Type: Ames test  
Result: positive

Test Type: Mouse Lymphoma  
Result: negative

Test Type: Chromosomal aberration  
Test system: human lymphoblastoid cells  
Result: negative

Test Type: DNA damage and repair, unscheduled DNA synthesis in mammalian cells (in vitro)  
Result: negative

Genotoxicity in vivo : Test Type: Micronucleus test  
Species: Mouse  
Cell type: Bone marrow  
Application Route: Oral  
Result: negative

Test Type: Cytogenetic assay  
Species: Rat  
Application Route: Oral  
Result: negative

Test Type: DNA Repair  
Species: Mouse  
Application Route: Oral  
Result: negative

### Carcinogenicity

Not classified based on available information.

### Components:

#### Lactic acid:

Species : Rat  
Application Route : Ingestion  
Exposure time : 2 Years  
Result : negative  
Remarks : Based on data from similar materials

#### Halofuginone:

Species : Mouse  
Application Route : Oral  
NOAEL : 0,24 mg/kg body weight  
Result : negative

Species : Rat  
Application Route : Oral  
Exposure time : 63 weeks

## Halofuginone Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
5.1	30.09.2023	862857-00018	Date of first issue: 26.08.2016

---

NOAEL	:	0,36 mg/kg body weight
Result	:	negative
Species	:	Rat
Application Route	:	Oral
Exposure time	:	26 Months
NOAEL	:	0,09 - 0,18 mg/kg body weight
Result	:	negative

**Reproductive toxicity**

Not classified based on available information.

**Components:****Lactic acid:**

Effects on fetal development : Test Type: Embryo-fetal development  
Species: Mouse  
Application Route: Ingestion  
Result: negative

**Halofuginone:**

Effects on fertility : Test Type: Fertility  
Species: Mouse  
Application Route: Oral  
Fertility: NOAEL: 0,126 mg/kg body weight  
Result: No effects on fertility.

Test Type: Fertility  
Species: Dog  
Application Route: Oral  
Fertility: LOAEL: 0,067 mg/kg body weight  
Result: Effects on fertility.

Test Type: Three-generation reproduction toxicity study  
Species: Mouse  
Application Route: Oral  
General Toxicity F1: LOAEL: 0,063 mg/kg body weight  
Symptoms: Reduced body weight  
Result: No effects on fertility and early embryonic development were detected.

Effects on fetal development : Test Type: Embryo-fetal development  
Species: Rat  
Application Route: Oral  
General Toxicity Maternal: LOAEL: 0,34 mg/kg body weight  
Embryo-fetal toxicity.: NOAEL: 0,67 mg/kg body weight  
Result: No embryo-fetal toxicity., No teratogenic effects.

Test Type: Embryo-fetal development  
Species: Rabbit  
Application Route: Oral  
General Toxicity Maternal: NOAEL: 0,025 mg/kg body weight  
Embryo-fetal toxicity.: NOAEL: 0,076 mg/kg body weight  
Result: No embryo-fetal toxicity., No teratogenic effects.

## Halofuginone Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
5.1	30.09.2023	862857-00018	Date of first issue: 26.08.2016

---

Reproductive toxicity - Assessment : Some evidence of adverse effects on sexual function and fertility, based on animal experiments.

### STOT-single exposure

Not classified based on available information.

### STOT-repeated exposure

Not classified based on available information.

### Components:

#### Halofuginone:

Target Organs : Blood  
 Assessment : Causes damage to organs through prolonged or repeated exposure.

### Repeated dose toxicity

### Components:

#### Lactic acid:

Species : Rat  
 NOAEL : > 100 mg/kg  
 Application Route : Ingestion  
 Exposure time : 13 Weeks  
 Remarks : Based on data from similar materials

Species : Rat  
 LOAEL : 886 mg/kg  
 Application Route : Skin contact  
 Exposure time : 13 Weeks

#### Halofuginone:

Species : Mouse  
 NOAEL : 0,07 mg/kg  
 LOAEL : 0,16 mg/kg  
 Application Route : Oral  
 Exposure time : 4 Weeks  
 Target Organs : Blood

Species : Rat  
 NOAEL : 0,13 mg/kg  
 LOAEL : 0,88 mg/kg  
 Application Route : Oral  
 Exposure time : 13 Weeks  
 Target Organs : Liver

Species : Dog  
 NOAEL : 0,067 mg/kg  
 LOAEL : 0,134 mg/kg  
 Application Route : Oral  
 Exposure time : 13 Weeks  
 Target Organs : Blood

## Halofuginone Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
5.1	30.09.2023	862857-00018	Date of first issue: 26.08.2016

---

Species	:	Dog
NOAEL	:	0,075 mg/kg
LOAEL	:	0,16 mg/kg
Application Route	:	Oral
Exposure time	:	26 Weeks
Target Organs	:	Blood

### Aspiration toxicity

Not classified based on available information.

### Experience with human exposure

#### Components:

#### Halofuginone:

General Information	:	No human information is available.
Inhalation	:	Remarks: May cause irritation of respiratory tract.
Skin contact	:	Remarks: May cause skin irritation and/or dermatitis. May cause sensitization by skin contact. Can be absorbed through skin.
Eye contact	:	Remarks: May irritate eyes.

---

## SECTION 12. ECOLOGICAL INFORMATION

### Ecotoxicity

#### Components:

#### Lactic acid:

Toxicity to fish	:	LC50 (Danio rerio (zebra fish)): > 100 mg/l Exposure time: 96 h Method: OECD Test Guideline 203 Remarks: Based on data from similar materials
Toxicity to daphnia and other aquatic invertebrates	:	EC50 (Daphnia magna (Water flea)): > 100 mg/l Exposure time: 48 h Method: OECD Test Guideline 202 Remarks: Based on data from similar materials
Toxicity to algae/aquatic plants	:	ErC50 (Pseudokirchneriella subcapitata (green algae)): > 100 mg/l Exposure time: 72 h Method: OECD Test Guideline 201 Remarks: Based on data from similar materials  NOEC (Pseudokirchneriella subcapitata (green algae)): > 100 mg/l Exposure time: 72 h Method: OECD Test Guideline 201 Remarks: Based on data from similar materials
Toxicity to microorganisms	:	EC50: > 10 - 100 mg/l Exposure time: 3 h Method: OECD Test Guideline 209

## Halofuginone Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
5.1	30.09.2023	862857-00018	Date of first issue: 26.08.2016

---

Remarks: Based on data from similar materials

**Halofuginone:**

Toxicity to fish : LC50 (Oncorhynchus mykiss (rainbow trout)): 1,8 mg/l  
Exposure time: 96 h  
Remarks: Based on data from similar materials

LC50 (Cyprinus carpio (Carp)): 0,3 mg/l  
Exposure time: 72 h  
Remarks: Based on data from similar materials

LC50 (Lepomis macrochirus (Bluegill sunfish)): 0,12 mg/l  
Exposure time: 96 h  
Remarks: Based on data from similar materials

Toxicity to daphnia and other aquatic invertebrates : EC50 (Daphnia magna (Water flea)): 0,02 mg/l  
Exposure time: 48 h  
Remarks: Based on data from similar materials

Toxicity to algae/aquatic plants : EC50 (Chlorella pyrenoidosa): 46 mg/l  
Method: OECD Test Guideline 201  
Remarks: Based on data from similar materials

M-Factor (Acute aquatic toxicity) : 10

M-Factor (Chronic aquatic toxicity) : 10

**Persistence and degradability****Components:****Lactic acid:**

Biodegradability : Result: Not readily biodegradable.  
Remarks: Based on data from similar materials

**Halofuginone:**

Biodegradability : Result: Not readily biodegradable.

**Bioaccumulative potential****Components:****Lactic acid:**

Partition coefficient: n-octanol/water : log Pow: -0,62

**Halofuginone:**

Partition coefficient: n-octanol/water : log Pow: 1,18

## Halofuginone Formulation

Version 5.1      Revision Date: 30.09.2023      SDS Number: 862857-00018      Date of last issue: 04.04.2023  
Date of first issue: 26.08.2016

---

### Mobility in soil

#### Components:

#### Halofuginone:

Distribution among environmental compartments : log Koc: 3,87  
Method: FDA 3.08

#### Other adverse effects

No data available

---

## SECTION 13. DISPOSAL CONSIDERATIONS

### Disposal methods

Waste from residues : Do not dispose of waste into sewer.  
Dispose of in accordance with local regulations.  
Contaminated packaging : Empty containers should be taken to an approved waste handling site for recycling or disposal.  
If not otherwise specified: Dispose of as unused product.

---

## SECTION 14. TRANSPORT INFORMATION

### International Regulations

#### UNRTDG

Not regulated as a dangerous good

#### IATA-DGR

Not regulated as a dangerous good

#### IMDG-Code

Not regulated as a dangerous good

#### Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code

Not applicable for product as supplied.

#### Special precautions for user

Not applicable

---

## SECTION 15. REGULATORY INFORMATION

### Safety, health and environmental regulations/legislation specific for the substance or mixture

Argentina. Carcinogenic Substances and Agents Registry : Not applicable

Control of precursors and essential chemicals for the preparation of drugs : Not applicable

### The ingredients of this product are reported in the following inventories:

AICS : not determined

DSL : not determined

---

## Halofuginone Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
5.1	30.09.2023	862857-00018	Date of first issue: 26.08.2016

---

IECSC : not determined

---

### SECTION 16. OTHER INFORMATION

Revision Date : 30.09.2023  
Date format : dd.mm.yyyy

#### Further information

Sources of key data used to compile the Material Safety Data Sheet : Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, <http://echa.europa.eu/>

#### Full text of other abbreviations

AllC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships Carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified

## Halofuginone Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
5.1	30.09.2023	862857-00018	Date of first issue: 26.08.2016

---

in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

AR / Z8